Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Infinity Pharmaceuticals

Status and phase

Withdrawn

Phase 2

Conditions

Dedifferentiated Liposarcoma

Treatments

Drug: IPI-504

Study type

Interventional

Funder types

Industry

Identifiers

NCT00969917

IPI-504-09

Details and patient eligibility

About

The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

At least 18 years of age at the time of signing informed consent.
Histologic diagnosis of dedifferentiated liposarcoma.
Available archival pathology specimen or tissue sample from a new biopsy for confirmation of diagnosis by central pathology reading.
At least one prior chemotherapy regimen for dedifferentiated liposarcoma.
No more than 2 prior chemotherapy regimens for dedifferentiated liposarcoma. Note: Any number of non-chemotherapy regimens is permitted.
Measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST (version 1.1) with at least one measurable lesion.
Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.
Life expectancy ≥6 months.

Exclusion criteria

Prior treatment with any heat shock protein 90 (Hsp90) inhibitor.
Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease
Patients with prior hepatic resections or hepatic-directed therapy
Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to dosing.